Table of Contents  
Year : 2014  |  Volume : 5  |  Issue : 3  |  Page : 186-192  

Metronomic chemotherapy

Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

Date of Submission05-Oct-2013
Date of Decision27-Dec-2013
Date of Acceptance16-Jan-2014
Date of Web Publication5-Jul-2014

Correspondence Address:
Rituparna Maiti
Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar - 751 019, Odisha
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0976-500X.136098

Rights and Permissions

Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called "metronomic chemotherapy" has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy. The knowledge gained from the preclinical studies of metronomic chemotherapy, along with clinical experience, will help to design better therapeutic protocols against cancer. Detailed pharmacogenomic and pharmacoproteomic studies on tumor endothelial cells and large multi-centered clinical trials, integrating bio-marker analyzes, are needed to investigate and validate the best treatment combinations for each tumor type and patient population.

Keywords: Anti-angiogenesis, conventional chemotherapy, metronomic chemotherapy, tumor dormancy

How to cite this article:
Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother 2014;5:186-92

How to cite this URL:
Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother [serial online] 2014 [cited 2022 Jan 29];5:186-92. Available from:

   Introduction Top

Despite considerable progress in cancer research, current treatment protocols are unable to cure certain malignancies. Moreover, conventional chemotherapy and even new drug delivery systems lead to adverse drug reactions that restrict dosing and interferes the efficacy of anti-neoplastic drugs. So exploring new therapeutic targets as well as new therapeutic strategies are essential to improve cancer treatment. The endothelium of tumor vasculature has been recognized as a clinically validated therapeutic target and pioneering research work on this field was done by Folkman. [1] Over the past few decades, researchers have established that angiogenesis is the key factor in the local and metastatic growth of cancer. The discovery of the pivotal role of angiogenesis in tumor growth and metastasis has redefined chemotherapy and new protocols have emerged. In addition to rationally designed, molecularly targeted anti-angiogenic drugs such as anti-vascular endothelial growth factor (anti-VEGF) antibodies, many conventional and new pharmaceutical agents may have anti-angiogenic effects as an additional feature contributing to their treatment efficacy. [2],[3] The recent preclinical studies have suggested that frequent administration of low doses (1/10 th -1/3 rd of the maximum tolerated dose [MTD]) of certain anti-neoplastic drugs known as 'metronomic' chemotherapy, shows/enhances the anti-angiogenic property of the drugs. The effects of these metronomic protocols of anti-neoplastic agents may be further improved by concurrent administration of another agent that inhibits the processes of growth and tumor formation. The rationale behind the use of metronomic chemotherapy for longer duration is to minimize adverse drug reactions and to target both endothelial cells and tumor cells which are at proliferating stage. Hence, metronomic chemotherapy is defined as repeated administration of anti-neoplastic drugs at comparatively low doses frequently and without long drug-free period. [3] Previously, it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy.

   The Concept Top

According to the conventional chemotherapy regimens, anticancer drugs are administered in cycles near or at the MDT and they alternate with long drug-free period to allow the patient to recover from adverse drug reactions. This strategy is successful in controlling the disease process in a significant number of patients (both adult and pediatric) but leads to some complications. In addition, despite initial improvement, recurrence is a common problem in metastatic and high-risk cancers. The rationale and effectiveness of conventional MTD-based chemotherapy regimens and dose modification strategies has been questioned for many years, especially in patients with poor-prognosis and scientifically convincing research data were needed to support the potential of an alternative therapeutic strategy. [4] Thirteen years ago Browder et al., published such much-awaited preclinical data from Judah Folkman's laboratory and it was confirmed in Robert Kerbel's laboratory. [5],[6] For demonstrating the anti-angiogenic effect of low-dose chemotherapy, both the teams used transplantable tumors and xenograft models. [5],[6] The first study revealed that metronomic regimen of cyclophosphamide (CPA) was more effective than conventional therapy and could overcome drug resistance. [5] Whereas, the second study explored the existence of synergism between continuous treatment with low-dose vinblastine and anti-VEGF receptor (VEGFR) therapy. [6] The scientific basis for metronomic chemotherapy is that conventional anti-neoplastic drugs target vascular endothelial cell proliferation but the anti-angiogenetic effect cannot be sustained because endothelial cells get a chance to recover during treatment breaks and this may be overcome by frequent treatment at low doses. Hanahan et al. coined the term 'metronomic' which is derived from the word "metronome", a musical instrument that produces regular, metrical ticks representing fixed, regular aural pulse. [7] Metronomic chemotherapy is the frequent administration of chemotherapy drugs at doses below the MTD and with no prolonged drug-free break. It thus achieves a sustained low blood level of the drug without significant toxic side-effects. [8]

The main characteristics of metronomic chemotherapy are: [9]

  • Frequent (dose-dense) administration of chemotherapy without any interruptions
  • Using a biological optimized dose instead MTD
  • No application of hematopoietic growth factors
  • Preference for oral drugs
  • Low incidence of treatment related side-effects
  • Potential for delayed development of resistance.

   Difference from Conventional Chemotherapy Top

  • Conventional cytotoxic drugs are designed for use at MTD but in metronomic chemotherapy, doses lower than MTD are used
  • Conventional therapy is usually administered at defined intervals (3 weekly, fortnightly, weekly) as determined by the recovery of bone marrow but in metronomic therapy dosing frequency is continuous, e.g., weekly, every other day, daily
  • Metronomic therapy leads to sustained plasma concentration of the drug but rise and fall of the plasma concentration is the feature of conventional therapy
  • Metronomic therapy is targeted to endothelial cells in the growing vasculature of the tumor whereas conventional therapy targets proliferating tumor cells
  • The intention of convention therapy is to treat cancer directly by inhibiting or killing rapidly dividing tumor cells whereas metronomic chemotherapy is administered with the aim of achieving cancer control by targeting angiogenesis
  • Metronomic chemotherapy achieves a sustained low blood level of the drug without significant toxic side-effects and hence there is reduced need for supportive therapy. However in case of conventional therapy toxicity is a concern as doses are used at MTD
  • Conventional chemotherapy is, in general, more effective against the primary tumor than against metastasis. Most cytotoxic agents, even if given in combined schedules at MTD, achieve only palliation in patients with advanced cancer.

   Mechanism of Action Top

Metronomic chemotherapy is a multi-targeted therapy. Metronomic chemotherapy exerts both direct and indirect effects on tumor cells and their microenvironment. It can inhibit tumor angiogenesis, stimulate anticancer immune response and also induces tumor dormancy.

Anti-angiogenic properties

Metronomic chemotherapy exerts its anti-cancer activity mainly by inhibiting tumor angiogenesis. Metronomic protocol of drug administration has been proved to increase the anti-angiogenic properties of some chemotherapeutic drugs in-vitro significantly, such as CPA and taxanes. [10]

The mechanisms of action of anti-angiogenic activity of metronomic chemotherapy have been demonstrated in-vivo. These include: [11]

  • Proliferation and/or induction of apoptosis of activated endothelial cells is selectively inhibited
  • Selective inhibition of migration of endothelial cell,
  • Increase in the expression of thrombospondin-1, an endogenous inhibitor of angiogenesis
  • Sustained decrease in levels and viability of bone marrow-derived endothelial progenitor cells (CEPs).

Endothelial toxicity is a common phenomenon in anti-cancer therapy. Anti-angiogenic dose of a drug that is higher than the dose required to kill malignant cells should not be considered anti-angiogenic. There are some well-defined criteria, which are necessary to be fulfilled for defining chemotherapy with anticancer agents as metronomic. The criteria for an anti-angiogenic approach of metronomic chemotherapy are: [9]

  • Strong differential cytotoxicity between cancer cells and endothelial cells
  • Dynamic contrast enhanced magnetic resonance imaging or contrast enhanced ultrasonic examinations detecting changes in the permeability and blood-flow in tumors suggesting altered function of endothelial cells
  • Changes of mechanistic effects (e.g., biomarker changes: IL-1 and 6, VEGF, VEGFR1 and 2, bFGF, Ang 1 and 2, MMP-2 and 9, vessel density etc.)
  • Inhibition of angiogenesis in-vivo and in-vitro (in-vivo models at best only with spontaneous, slow growing tumors).

Activation of immunity

Both innate and adaptive immune system have an important role in the development and control of cancer. The well-known adverse effects of chemotherapy on the immune system are neutropenia and lymphopenia but various studies have proved and reviewed that some cytotoxic drugs, such as anthracyclines, taxanes and CPA, possess immune-stimulatory properties. [12] In this context, the effect on regulatory T cells (T reg ) is quite relevant for metronomic treatments. T reg are CD4 + CD25 + Foxp3 + lymphocytes that can inhibit antigen-specific immune response both in a cytokine-dependent and cell contact-dependent manner. [13] T reg can thus inhibit anti-tumor immune response by suppressing the activity of both tumor-specific (CD8 + cytotoxic T lymphocytes and CD4 + T helper cells) and tumor-unspecific effector cells (natural killer [NK] and NK T cells). [13] In a variety of human cancers, T reg cells have been found in increased proportions which can correlate with tumor progression and lack of treatment response. [14] So, impairment of T reg activity by either specific blockade or depletion is a method to enhance immune response against tumor-associated antigens. [13] Many studies (preclinical and clinical) have documented the effect of low dose CPA on T reg cells. It reduces the number of T reg cells, suppresses the function of the T reg cells and increases both lymphocyte proliferation and memory T cells. [15]

In addition, this therapy also induces dendritic cell maturation and thus has the immune-stimulatory effect. Tanaka et al., found that metronomic chemotherapy regimens of some of the chemotherapeutic drugs such as vinblastine, paclitaxel and etoposide could promote dendritic cell maturation at non-toxic concentrations. [16]

Induction of tumor dormancy

Tumor dormancy occurs as a result of cell-cycle arrest or from a dynamic equilibrium state in which cell proliferation is balanced by induction of apoptosis. Tumor dormancy can be observed during the early phase of cancer progression and also after completion of anticancer treatments during the remission phase where tumors can resume their growth from remaining residual disease. [17] Suppression of angiogenesis, apoptosis of malignant cells and immune-surveillance are three main methods by which metronomic chemotherapy induces tumor dormancy. [8]

Induction of senescence

Lower grade of damage by chemotherapeutic agents may start senescence associated with antiproliferative responses. The cascades of caspase activity that induce cellular apoptosis are not activated. A dose of 250 nM doxorubicin causes apoptosis of prostatic cells, whereas its one-tenth dose (25 nM) triggers senescence. Deoxyribonucleic acid damage leading to single- and double-strand breaks have been induced by many senescence-inducing drugs. The induction of senescence in tumors can be achieved by repetitive, low-dose regimens of cytostatic drugs. [18],[19]

Four-dimensional effect

Drug driven dependency/deprivation or a 4-D phenomenon has been hypothesized by André and Pasquier to explain the efficacy of the drug regimens using intermittent drug interruptions. According to this postulation, tumor cells become dependent on chemotherapeutic agents during long exposures and sudden withdrawal or replacement therapy may lead to cell death. This hypothesis may be used to explain the situations where multiple drugs are used with differing periods of administration. [20]

   Drugs Used in Metronomic Chemotherapy Top

Metronomic chemotherapy regimen is usually a combination of various drugs of different classes having anti-angiogenic, immune-stimulatory and apoptotic properties. Frequent and repetitive administration of low dose of some antineoplastic drugs (CPA, methotrexate, etoposide, vinblastine, paclitaxel) is cytotoxic to both circulating endothelial cells and circulating CEPs but has no effect on non-endothelial cells and leucocytes. [5] Due to their relative genetic stability, endothelial cells are inherently less susceptible to the development of drug resistance than are tumor cells. [6] It has been observed that in certain conditions when maximally tolerated doses of chemotherapy drugs are no longer effective, significant inhibition of tumor growth can be achieved by switching over to a metronomic regimen.

Metronomic chemotherapy in adults

Most of clinical trials on metronomic chemotherapy in adults have been conducted in patients with breast carcinoma. [21],[22] Many investigators have used various metronomic chemotherapy regimen for patients with advanced and recurrent ovarian carcinoma, advanced multiple myeloma, hormone resistant prostate cancer, non-Hodgkin lymphoma and others. [23] Some well-studied metronomic regimens for adults have been listed in [Table 1] and most of these studies have showed modest response rate to metronomic chemotherapy and overall clinical benefit.
Table 1: Metronomic chemotherapy regimens used in adults

Click here to view

Metronomic chemotherapy in pediatric patients

Metronomic chemotherapy has the potential to improve survival and quality of life of pediatric cancer patients by reducing the burden of adverse effects. number of clinical trials of metronomic chemotherapy in pediatric population is limited in number but some of the results are very promising [Table 2]. In a study published in 2002, Sterba et al., demonstrated the effect of metronomic temozolomide in combination with radiotherapy in children with medulloblastoma. Later they conducted a pilot study of a four-drug metronomic chemotherapy regimen in children with relapsed solid tumors. [32] Metronomic etoposide and metronomic temozolomide was evaluated through combined oral maintenance bio-differentiating and anti-angiogenic therapy protocol by Sterba et al., in 2006. [29] In another study, 20 children with recurrent or progressive cancer of various tumors were treated and evaluated with metronomic chemotherapy regimen, involving thalidomide and celecoxib with alternating metronomic etoposide and CPA. [30]
Table 2: Metronomic chemotherapy regimens used in pediatric age group

Click here to view

   Optimal Biologic Dose and Biomarkers Top

Low-dose regimen of metronomic chemotherapy is a promising strategy in cancer treatment ensuring advantages such as low toxicity, increased efficacy, good activity against resistant tumors and ability to combine chemotherapeutic agents. However, an important disadvantage of this type of regimen is the empiricism in finding the optimal 'low-dose' or OBD and in monitoring therapeutic efficacy during the course of treatment. Because the predominant mechanism for metronomic chemotherapy is thought to be anti-angiogenesis, as a result of targeting both dividing endothelial cells in a tumor's growing vasculature and bone marrow derived circulating VEGFR-2 + cells, including CEPs, Yuval Shaked et al., have investigated some cellular pharmacodynamic biomarkers for determining OBD of different metronomic regimens-(i) previous observations showing significant and sustained declines in circulating VEGFR-2 + CEPs induced by prolonged daily low-dose metronomic chemotherapy; (ii) preclinical validation of measuring levels of such cells as a surrogate blood-based marker of angiogenesis and targeted anti-angiogenic drug activity, including optimal biologic dosing; and (iii) CEP potentially as a marker in the clinic of targeted anti-angiogenic drug activity. They also found a correlation between each OBD with the maximum reduction in viable peripheral blood circulating VEGFR-2 + CEPs. These results suggest that CEPs may help as a surrogate biomarker to determine the OBD of metronomic chemotherapy regimens and can reduce the level of empiricism. [33]

   Toxicity of Metronomic Chemotherapy Top

Most of the clinical trials demonstrated that metronomic chemotherapy was well-tolerated. In addition, metronomic chemotherapy may be a cost-effective treatment option as evaluated in various clinical trials. [30] High-grade toxic effects were either rare or not found. Most common toxic effects were mild nausea and/or vomiting, mild to moderate anemia, neutropenia, leucopoenia and lymphopenia as well as low-grade fatigue. [9] Overall, metronomic chemotherapy offers a significant clinical improvement including improvement in quality of life with minimal toxicity. However, data are still not adequate to draw definitive conclusions regarding the tolerance of these drug combinations.

While using metronomic chemotherapy for a longer period, especially in children, some potential risks and concerns must be taken into consideration. Prolonged metronomic chemotherapy may lead cumulative toxicity of anticancer agents, which can lead to secondary diseases. For example, cumulative dose of etoposide or temozolomide can lead to secondary leukemia. [34],[35] Although physiologic angiogenesis differs from tumor neoangiogenesis, special attention must be given to the growth and development of young children receiving metronomic chemotherapy. A recent study has found potential association of subdural hematoma in a child with medulloblastoma, with metronomic chemotherapy. [36] So careful monitoring of children receiving metronomic chemotherapy is must in any future studies.

   Resistance Top

One main obstacle in chemotherapy is the occurrence of resistance against the applied treatment regimen. Anti-angiogenic drug regimen targeting endothelial cells are unlikely to produce acquired drug resistance as endothelial cells were expected to be genetically stable. However, some experimental and clinical studies have established the development of escape mechanisms against anti-angiogenic treatment regimens also and support a hypothesis that two mechanisms of unconventional resistance can develop - evasive resistance, an adaptation to prevent specific anti-angiogenic effect; and intrinsic or pre-existing tolerance. Different methods in different tumor types may lead to manifestation of both evasive and intrinsic resistance. Cells developing resistance to metronomic chemotherapy undergo a complex molecular evolution. Changes in many different factors and pathways contribute to the formation of a resistant phenotype. One important category of resistance to anti-angiogenic therapy is "reduced vascular dependence." This resistance mechanism applies here, as the resistant tumor grows under conditions of hypoxia and restricted nutrients without the formation of additional tumor vessels. During anti-angiogenic treatment, blood vessels are destroyed and coagulation takes place. So anti-coagulation properties of the cells could be part of a complex resistance mechanism. So metronomic chemotherapy also can lead to resistance which demands assessment of their prevalence and importance. [37],[38]

   Pharmacogenetics Top

Data on pharmacogenetics of metronomic chemotherapy is still lacking. Gene expression profiling and comprehensive gene expression analysis of the resistant tumors can guide in choosing correct metronomic therapy. Gene expression of resistant tumors clearly differs from non-resistant tumors and to investigate the molecular basis of in-vivo resistance mechanism genome-wide microarray studies are required. Some studies revealed that expression of resistance-related genes in vivo differs from gene expression in vitro, indicating an involvement of micro-environmental factors leading to the observed in vivo resistance. [38]

Orlandi et al., evaluated the association between VEGF-A sequence variants and prostate-specific antigen progression, progression-free survival and overall survival, in advanced castration-resistant prostate cancer patients treated with metronomic CPA (CTX), celecoxib and dexamethasone. [39] Pharmacogenomics of bortezomib has been investigated by John D. Shaughnessy et al. [40] In another study, Mercurio et al., have quantified the expression of several genes (ICAM1, CRK, CD36 and IQGAP1) by reverse transcriptase quantitative polymerase chain reaction in pilocytic astrocytomas and glioblastomas. Those genes were all significantly over-expressed in hypothalamic-chiasmatic pilocytic astrocytomas relative to cerebellar pilocytic astrocytomas and CRK and ICAM1 were significantly over-expressed in pilocytic astrocytomas versus glioblastomas. These over-expressed genes are a new target of therapy and refractory multifocal pilocytic astrocytoma was treated with fluvastatin/celecoxib for 18 months successfully. This new strategy is promising for the treatment of refractory pilocytic astrocytoma. [41] Kubisch et al., worked on metronomic anti-angiogenic treatment of xenografted prostate cancer tumors in severe combined-immunodeficiency mice with CPA. To investigate the complex molecular changes occurring during resistance formation, they performed a comprehensive gene expression analysis of the resistant tumors in vivo and observed a multitude of differentially expressed genes, e.g., PAS domain containing protein 1, annexin A3 (ANXA3), neurotensin, plasminogen activator tissue, when comparing resistant to in-vivo passaged tumor samples. Such studies can give insight into the mechanism of resistance and can explore new molecular targets of metronomic chemotherapy. [38]

   Future Perspective Top

Evidence from pre-clinical and clinical studies has established metronomic chemotherapy as a new treatment strategy to control certain types of malignancies. However, optimizing a metronomic anticancer therapy is still a challenging task even after a decade of clinical investigation. So future cancer research should aim to identify the best agents to use according to tumor type, to calculate the doses of each agent to be used alone or in combination and to define the timing of drug administration. New strategies are being developed in the oncology clinic to combine metronomic chemotherapy with conventional chemotherapy, radiotherapy and/or targeted therapy and such strategies can explore infinite number of potential combinations. But in-depth pharmacogenetic and pharmacoproteomic studies on tumor endothelial cells are now needed to assess their sensitivity to metronomic chemotherapy and to determine the most effective drug combination to use in the clinic.

   References Top

1.Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.  Back to cited text no. 1
2.Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.  Back to cited text no. 2
3.Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.  Back to cited text no. 3
4.Weitman SD, Glatstein E, Kamen BA. Back to the basics: The importance of concentrationxtime in oncology. J Clin Oncol 1993;11:820-1.  Back to cited text no. 4
5.Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.  Back to cited text no. 5
6.Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.  Back to cited text no. 6
7.Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.  Back to cited text no. 7
8.Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: Old drugs in new package. Indian J Pediatr 2012;79:1617-22.  Back to cited text no. 8
9.Mross K, Steinbild S. Metronomic anti-cancer therapy - An ongoing treatment option for advanced cancer patients. J Cancer Ther Res 2012;1:32.  Back to cited text no. 9
10.Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.  Back to cited text no. 10
11.Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment. Curr Cancer Drug Targets 2007;7:566-81.  Back to cited text no. 11
12.Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.  Back to cited text no. 12
13.Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz) 2008;56:181-91.  Back to cited text no. 13
14.Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. CD4(+) CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064-71.  Back to cited text no. 14
15.Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 (+) 25+T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.  Back to cited text no. 15
16.Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 2009;69:6978-86.  Back to cited text no. 16
17.Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.  Back to cited text no. 17
18.Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102:1536-46.  Back to cited text no. 18
19.Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005;7:816-23.  Back to cited text no. 19
20.André N, Pasquier E. Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'. Nat Clin Pract Oncol 2009;6:E1.  Back to cited text no. 20
21.Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.  Back to cited text no. 21
22.Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225.  Back to cited text no. 22
23.Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.  Back to cited text no. 23
24.Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: Antitumor activity and biological effects. Ann Oncol 2006;17:232-8.  Back to cited text no. 24
25.Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009;15:4954-62.  Back to cited text no. 25
26.Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-8.  Back to cited text no. 26 Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001;59:50-6.  Back to cited text no. 27
28.Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer 2009;9:388.  Back to cited text no. 28
29.Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study. Onkologie 2006;29:308-13.  Back to cited text no. 29
30.Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-81.  Back to cited text no. 30
31.Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-8.  Back to cited text no. 31
32.Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002;49:117-20.  Back to cited text no. 32
33.Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.  Back to cited text no. 33
34.Le Deley MC, Vassal G, Taïbi A, Shamsaldin A, Leblanc T, Hartmann O. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 2005;45:25-31.  Back to cited text no. 34
35.De Vita S, De Matteis S, Laurenti L, Chiusolo P, Reddiconto G, Fiorini A, et al. Secondary Ph+acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005;84:760-2.  Back to cited text no. 35
36.Rome A, André N, Scavarda D, Gentet JC, De Paula AM, Padovani L, et al. Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis. Pediatr Blood Cancer 2009;53:246-7.  Back to cited text no. 36
37.Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.  Back to cited text no. 37
38.Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, et al. A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl Oncol 2013;6:1-9.  Back to cited text no. 38
39.Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer 2013;109:957-64.  Back to cited text no. 39
40.Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011;118:3512-24.  Back to cited text no. 40
41.Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, et al. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathol Commun 2013;1:17.  Back to cited text no. 41


  [Table 1], [Table 2]

This article has been cited by
1 A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy
Ruby Maharjan, Jeong Uk Choi, Seho Kweon, Rudra Pangeni, Na Kyeong Lee, Seong Jin Park, Kwan-Young Chang, Jin Woo Park, Youngro Byun
Biomaterials. 2022; 281: 121334
[Pubmed] | [DOI]
2 Stewart-Treves syndrome in an older woman successfully treated by metronomic chemotherapy: case report and literature survey
Stephanie Maréchal, Pierre Reginster, Antoine de Muylder, Arvne Servais, Eugene Mutijima, Christian Focan
Anti-Cancer Drugs. 2022; 33(2): 220
[Pubmed] | [DOI]
3 Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions
Eric D. Eisenmann, Zahra Talebi, Alex Sparreboom, Sharyn D. Baker
Basic & Clinical Pharmacology & Toxicology. 2021;
[Pubmed] | [DOI]
4 Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging
Elham Seyyednia, Fatemeh Oroojalian, Behzad Baradaran, Javid Shahbazi Mojarrad, Ahad Mokhtarzadeh, Hadi Valizadeh
Journal of Controlled Release. 2021; 338: 367
[Pubmed] | [DOI]
5 A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer
Rui Zhang, Ge Cheng, Shengnan Liu, Hongying Lv, Juan Li
Journal of Materials Chemistry B. 2021; 9(42): 8809
[Pubmed] | [DOI]
6 Metabolic Drivers of Invasion in Glioblastoma
Joseph H. Garcia, Saket Jain, Manish K. Aghi
Frontiers in Cell and Developmental Biology. 2021; 9
[Pubmed] | [DOI]
7 PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
Hugo Christian Monroy-Ramirez, Marina Galicia-Moreno, Ana Sandoval-Rodriguez, Alejandra Meza-Rios, Arturo Santos, Juan Armendariz-Borunda
International Journal of Molecular Sciences. 2021; 22(15): 8298
[Pubmed] | [DOI]
8 Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
Anindita Chakrabarty, Shayantani Chakraborty, Ranjini Bhattacharya, Goutam Chowdhury
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
9 Metronomic Chemotherapy
Marina Elena Cazzaniga, Nicoletta Cordani, Serena Capici, Viola Cogliati, Francesca Riva, Maria Grazia Cerrito
Cancers. 2021; 13(9): 2236
[Pubmed] | [DOI]
10 Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers
Przemyslaw Kozminski, Pawel Krzysztof Halik, Raphael Chesori, Ewa Gniazdowska
International Journal of Molecular Sciences. 2020; 21(10): 3483
[Pubmed] | [DOI]
11 Antitumor, Immunomodulatory and Antiangiogenic Efficacy of Medicinal Mushroom Extract Mixtures in Advanced Colorectal Cancer Animal Model
Boris Jakopovic, Nada Oršolic, Sandra Kraljevic Pavelic
Molecules. 2020; 25(21): 5005
[Pubmed] | [DOI]
12 Metronomics in Pediatric Oncology: Lessons Learned and the Way Forward
Raja Pramanik, Sameer Bakhshi
Indian Journal of Medical and Paediatric Oncology. 2020; 41(03): 317
[Pubmed] | [DOI]
13 The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Christiana M. Neophytou, Chryso Pierides, Maria-Ioanna Christodoulou, Paul Costeas, Theodora-Christina Kyriakou, Panagiotis Papageorgis
Frontiers in Oncology. 2020; 10
[Pubmed] | [DOI]
14 Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models
Chun-Chieh Yeh, Pei-Ying Liao, Sudhir Pandey, Su-Yung Yung, Hsueh-Chou Lai, Long-Bin Jeng, Wei-Chun Chang, Wen-Lung Ma
Frontiers in Oncology. 2020; 10
[Pubmed] | [DOI]

Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer

Rudra Pangeni, Laxman Subedi, Saurav Kumar Jha, Seho Kweon, Seo-Hee Kang, Kwan-Young Chang, Jeong Uk Choi, Youngro Byun, Jin Woo Park
International Journal of Nanomedicine. 2020; Volume 15: 7719
[Pubmed] | [DOI]
16 Efficiency of Different Treatment Regimens Combining Anti-tumor and Anti-inflammatory Liposomes for Metastatic Breast Cancer
Jingxuan Liu, Yuqing Sun, Xiao Liu, Yueying Yang, Andy Samuel Widjaya, Zhiguo Long, Yanyan Jiang
AAPS PharmSciTech. 2020; 21(7)
[Pubmed] | [DOI]
17 Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
Robert S. Epstein, Matti S. Aapro, Upal K. Basu Roy, Tehseen Salimi, JoAnn Krenitsky, Megan L. Leone-Perkins, Cynthia Girman, Courtney Schlusser, Jeffrey Crawford
Advances in Therapy. 2020; 37(8): 3606
[Pubmed] | [DOI]
18 Role of nitric oxide in the response to photooxidative stress in prostate cancer cells
Francesca D'Este, Emilia Della Pietra, Gretta Veronica Badillo Pazmay, Luigi E. Xodo, Valentina Rapozzi
Biochemical Pharmacology. 2020; 182: 114205
[Pubmed] | [DOI]
19 Enhanced treatment of lung cancer by metronomic therapy with oral pemetrexed
Kinam Park
Journal of Controlled Release. 2018; 284: 250
[Pubmed] | [DOI]
20 Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
Marina E. Cazzaniga,Elisabetta Munzone,Emilia Montagna,Giovanni Pappagallo
Expert Review of Anticancer Therapy. 2018; 18(8): 805
[Pubmed] | [DOI]
21 Lapatinib nano-delivery systems: a promising future for breast cancer treatment
Gunjan Vasant Bonde,Sarita Kumari Yadav,Sheetal Chauhan,Pooja Mittal,Gufran Ajmal,Sathish Thokala,Brahmeshwar Mishra
Expert Opinion on Drug Delivery. 2018; : 1
[Pubmed] | [DOI]
22 Potentiating cancer vaccine efficacy in liver cancer
Maria Tagliamonte,Annacarmen Petrizzo,Angela Mauriello,Maria Lina Tornesello,Franco M Buonaguro,Luigi Buonaguro
OncoImmunology. 2018; : 1
[Pubmed] | [DOI]
23 Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Sara Musetti, Leaf Huang
ACS Nano. 2018; 12(12): 11740
[Pubmed] | [DOI]
24 Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
Maria Grazia Cerrito, Marco De Giorgi, Davide Pelizzoni, Sara Maria Bonomo, Nunzio Digiacomo, Arianna Scagliotti, Cristina Bugarin, Giuseppe Gaipa, Emanuela Grassilli, Marialuisa Lavitrano, Roberto Giovannoni, Paolo Bidoli, Marina Elena Cazzaniga
Oncotarget. 2018; 9(44): 27448
[Pubmed] | [DOI]
25 Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
Pierpaolo Pastina, Valerio Nardone, Cirino Botta, Stefania Croci, Paolo Tini, Giuseppe Battaglia, Veronica Ricci, Maria Grazia Cusi, Claudia Gandolfo, Gabriella Misso, Silvia Zappavigna, Michele Caraglia, Antonio Giordano, Donatella Aldinucci, Pierfrancesco Tassone, Pierosandro Tagliaferri, Luigi Pirtoli, Pierpaolo Correale
Oncotarget. 2017; 8(44): 75904
[Pubmed] | [DOI]
26 The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field
T. B. Gaspar,J. Henriques,L. Marconato,F. L. Queiroga
Veterinary and Comparative Oncology. 2017;
[Pubmed] | [DOI]
27 Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study
R. M. Wouda,S. E. Hocker,M. L. Higginbotham
Veterinary and Comparative Oncology. 2017;
[Pubmed] | [DOI]
28 Immunotherapy for the treatment of breast cancer
Mariela A. Moreno Ayala,Maria Florencia Gottardo,Antonela S. Asad,Camila Zuccato,Alejandro Nicola,Adriana Seilicovich,Marianela Candolfi
Expert Opinion on Biological Therapy. 2017; 17(7): 797
[Pubmed] | [DOI]
29 The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity
Wen-Ying Liao,Tze-Sian Chan,Kelvin K. Tsai
Journal of Cancer Research and Practice. 2017;
[Pubmed] | [DOI]
30 The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine
Wei-Ping Lee,Keng-Hsin Lan,Chung-Pin Li,Yee Chao,Ming-Chih Hou,Han-Chieh Lin,Shou-Dong Lee
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2017; 1863(4): 917
[Pubmed] | [DOI]
31 A Commentary: Herbal Medicine Offers Great Potential in Support of Metronomic Cancer Therapy
Clara Bik-San Lau,Chun-Kwok Wong,Ping-Chung Leung
Journal of Cancer Therapy. 2017; 08(02): 86
[Pubmed] | [DOI]
32 Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
Connie Rabanal,Rossana Ruiz,Silvia Neciosup,Henry Gomez
World Journal of Clinical Oncology. 2017; 8(6): 437
[Pubmed] | [DOI]
33 Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model
Amr S. Abu Lila,Naoto Moriyoshi,Masakazu Fukushima,Cheng-Long Huang,Hiromi Wada,Tatsuhiro Ishida
Cancer Letters. 2016;
[Pubmed] | [DOI]
34 Metronomic chemotherapy and nanocarrier platforms
Amr S. Abu Lila,Tatsuhiro Ishida
Cancer Letters. 2016;
[Pubmed] | [DOI]
35 Combinatorial immunotherapy strategies for hepatocellular carcinoma
Maria Tagliamonte,Annacarmen Petrizzo,Maria Lina Tornesello,Gennaro Ciliberto,Franco M Buonaguro,Luigi Buonaguro
Current Opinion in Immunology. 2016; 39: 103
[Pubmed] | [DOI]
36 A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma†
R. Finotello,J. Henriques,S. Sabattini,D. Stefanello,R. Felisberto,S. Pizzoni,R. Ferrari,L. Marconato
Veterinary and Comparative Oncology. 2016; : n/a
[Pubmed] | [DOI]
37 Refractory Choriocarcinoma: Complete Response With Oral Etoposide
Manikandan Dhanushkodi,Trivadi Ganesan,Tenali Gnana Sagar
Journal of Global Oncology. 2016; : JGO006049
[Pubmed] | [DOI]
38 Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells
Ursula Winter,Hebe A. Mena,Soledad Negrotto,Eloisa Arana,Guillem Pascual-Pasto,Viviana Laurent,Mariona Suñol,Guillermo L. Chantada,Angel M. Carcaboso,Paula Schaiquevich,Francesco Bertolini
PLOS ONE. 2016; 11(7): e0160094
[Pubmed] | [DOI]
39 Cancer vaccines for hepatocellular carcinoma: future directions
Franco M Buonaguro,Luigi Buonaguro
Immunotherapy. 2016; 8(4): 391
[Pubmed] | [DOI]
40 Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma
Zeng Wang-Yuan,Zeng Jiang-Zheng,Yan-Da Lu,Xin-Bao Hao,Tao Hong,Fen Huang,Jun-Hua Lei,Zhi-Hui He,Mei-zhu Huang
International Journal of Hyperthermia. 2015; : 1
[Pubmed] | [DOI]
41 Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer
Roberto Petrioli,Giandomenico Roviello,Anna Ida Fiaschi,Letizia Laera,Salvatora Tindara Miano,Daniele Marrelli,Franco Roviello,Vincenzo Bianco,Edoardo Francini
Future Oncology. 2015; 11(18): 2563
[Pubmed] | [DOI]
42 Head and neck cancer: metronomic chemotherapy
Francesca De Felice,Daniela Musio,Vincenzo Tombolini
BMC Cancer. 2015; 15(1)
[Pubmed] | [DOI]
43 From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
Karolina Vernmark,Maria Albertsson,Bergthor Björnsson,Thomas Gasslander,Per Sandström,Xiao-Feng Sun,Annika Holmqvist
BMC Cancer. 2015; 15(1)
[Pubmed] | [DOI]
44 Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva,David J. Waxman,Giannoula Lakka Klement
Cancer Letters. 2015; 358(2): 100
[Pubmed] | [DOI]
45 Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
Gabriella Ferrandina,Giacomo Corrado,Floriana Mascilini,Paola Malaguti,Riccardo Samaritani,Mariagrazia Distefano,Valeria Masciullo,Alessia Di Legge,Antonella Savarese,Giovanni Scambia
BMC Cancer. 2014; 14(1): 947
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   The Concept
    Difference from ...
   Mechanism of Action
    Drugs Used in Me...
    Optimal Biologic...
    Toxicity of Metr...
   Future Perspective
    Article Tables

 Article Access Statistics
    PDF Downloaded1821    
    Comments [Add]    
    Cited by others 45    

Recommend this journal